Croda Delivers Solid H1 Growth, Eyes £100m Cost Savings by 2027
Croda International’s first-half results for 2025 reveal a company navigating economic headwinds with discipline. While currency fluctuations provided some unwelcome turbulence, the underlying performance shows resilience across key divisions. Let’s unpack what matters for investors.
Sales Growth: Volume Leads the Charge
Group sales grew 7.3% at constant currency to £855.8m, driven primarily by higher sales volumes (+11%). This wasn’t a one-division story:
- Consumer Care (+7%): Standout performer Fragrances & Flavours (F&F) surged 17%, supported by Beauty Care (+3%) and Home Care (+7%). Beauty Actives (+1%) faced softer premium demand in North America.
- Life Sciences (+9%): Strong recovery in agriculture, with Seed Enhancement up 17% and Crop Protection up 12%. Pharma grew a steady 5%.
- Industrial Specialties (+4%): Direct sales grew 12%, though sales via the legacy supply agreement declined.
Regionally, EMEA led the pack with 12% constant currency growth, followed by Asia (6%), Latin America (5%), and North America (3%). Q2 sales (+6% cc) moderated slightly from Q1’s strong start, reflecting seasonality in Crop Protection and softer US consumer confidence.
Profitability & Margins: Efficiency Offsets FX Pain
Adjusted operating profit rose 8% at constant currency to £146.9m. The adjusted operating margin improved to 17.2% (H1 2024: 16.6%), a positive signal showing operational leverage and early benefits from cost initiatives. However, this was hard-won:
- Currency Headwinds: Sterling strength knocked £4.8m off adjusted operating profit and £4.5m off adjusted PBT. Further FX drag is anticipated in H2 (£5m estimated). Transactional FX impacts cost another £6.7m.
- Price/Mix Pressure: Overall price/mix was down 4%, reflecting competitive dynamics and customer mix shifts (e.g., strong growth in the relatively lower-margin F&F segment).
Adjusted basic EPS grew 4.9% to 72.2p. Statutory results were significantly impacted by £27.3m in impairment charges (mainly European distribution rationalisation) and other adjusting items.
The Big Push: £100m Cost Savings Target
The most significant strategic announcement is the increase in the annualised cost savings target to £100m by the end of 2027 (up from £40m). This ambitious plan targets:
- Operations & Supply Chain Excellence: ~£35m (Optimising manufacturing, warehousing, logistics)
- Procurement (Direct & Indirect): ~£30m
- Employee Costs: ~£25m (Reducing management layers, headcount)
- Enabling Functions (e.g., IT): ~£10m
Phased benefits are expected: ~£25m in 2025, ~£35m in 2026, ~£25m in 2027, reaching the full £100m run-rate by end-2027. The estimated cash cost is ~£80m, booked as exceptional charges over the period. This programme is central to driving margin recovery and offsetting inflation.
Driving Growth & Improving Returns
Croda’s five-point plan remains focused:
- Maximising Portfolio Returns: Success seen in Ceramides (sales ~+50% cc, low base) and F&F investments. Pharma lipids capacity (Lamar, PA & Leek, UK) commissioning in H2 is key.
- Leveraging Local & Regional (L&R) Customers: L&Rs now represent 81% of Consumer Care sales (up from 72% in 2019). Sales to L&R customers in Consumer Care grew 11% cc.
- Stepping Up Innovation: Sustained R&D intensity >4% of sales. 65 new patents filed in H1.
- Realigning Cost Base: The expanded savings programme.
- Optimising Capacity: Reviewing production/distribution assets underway (triggering H1 impairments).
The company is also targeting improved working capital management (receivables and inventory days) and moderating capex intensity.
Balance Sheet & Cash Flow
Free cash flow was £34.2m (H1 2024: £122.7m), reflecting a working capital outflow of £60.7m (vs inflow last year) and lower capex (£59.5m). Net debt increased to £580.1m (H1 2024: £507.9m), with a leverage ratio of 1.5x EBITDA, comfortably within the target range (1-2x). The interim dividend increased by 2.1% to 48.0p per share.
Outlook: Confidence Maintained
Despite acknowledging ongoing “unpredictable political and economic environment” creating uncertainty, Croda reaffirmed its full-year 2025 guidance. The Group continues to expect adjusted profit before tax (at constant currency) between £265m and £295m.
The Takeaway: Execution is Key
Croda’s H1 demonstrates underlying volume growth and margin resilience, albeit masked by significant FX impacts and strategic restructuring charges. The bold expansion of the cost savings target to £100m signals a clear focus on operational efficiency and margin improvement over the medium term. While currency remains a persistent headwind, maintaining full-year guidance amidst volatility provides reassurance. Investors will watch closely for progress on the cost programme and the conversion of innovation (especially in Pharma and F&F) into sustained, profitable growth. The Q3 update on 16th October will be the next checkpoint.
